Tag: growth-stock
Viasat Stock Analysis: Buy or Sell? Valuation, Leverage & Growth
Viasat, Inc. (VSAT) is rated Sell as the stock prices in a recovery that operating results have not yet earned. Revenue was flat in Q1 2026, and the 182.4x forward P/E plus 3.3x EV/revenue leave little room for satellite execution or leverage risk.
Cipher Digital Stock Analysis: Buy or Sell? Valuation, HPC Ramp & Cash Burn
Cipher Digital Inc. (CIFR) is rated Sell as the stock appears to discount a fast HPC monetization path despite only $34.8M of quarterly revenue and a $114.3M net loss. The main issue is execution: the site pipeline is large, but cash conversion has not yet caught up.
MasTec Stock Analysis: Valuation, Margin Pressure, FCF & Growth
MasTec Inc. (MTZ) carries a Sell rating as strong revenue growth is being offset by thin free cash flow and weak margin conversion. The stock’s high EV/EBITDA multiple assumes better operating leverage than the business has yet delivered.
Fortinet Stock Analysis: Valuation, Growth, Channel Risk & Margins
Fortinet (FTNT) is rated Sell in this stock analysis. The article says its premium valuation is hard to justify while revenue growth lags faster security peers, with channel concentration adding risk.
nLIGHT Stock Analysis: Defense Growth, Margins, Liquidity & Valuation
nLIGHT (LASR) is rated Hold as revenue growth in aerospace and defense is offset by weak operating margins and a valuation that already assumes improvement. The key issue is whether LASR can turn defense-led sales into durable EBITDA and cash flow.
Aehr Test Systems Stock Analysis: Valuation, Margins, Cash Flow & Customer Risk
Aehr Test Systems (AEHR) earns a SELL rating as its valuation far outpaces current earnings power. Revenue is falling, cash flow remains negative, and customer concentration adds meaningful execution risk despite a strong balance sheet.
Incyte Stock Analysis: Valuation, Patent Cliff, Cash Flow & Growth
Incyte (INCY) is rated Hold as strong cash generation and reasonable valuation are offset by the looming 2028 JAKAFI patent cliff. The company is profitable, but investors need OPZELURA, ZYNYZ and NIKTIMVO to scale fast enough to replace legacy franchise erosion.
Teradyne Stock Analysis: Valuation, AI Demand, Margins & Growth
Teradyne (TER) is rated HOLD as strong AI-driven growth and operating leverage are already offset by a steep valuation. Q1 2026 revenue rose 87% year over year, but customer concentration and rich multiples limit the upside.
Symbotic Stock Analysis: Valuation, Margins, Cash Flow & Growth
Symbotic (SYM) is rated Hold as revenue growth stays strong but profitability remains early. TTM operating margin was flat and customer concentration is high, even as debt is low and deployment-driven growth continues.
Boston Scientific Stock Analysis: Valuation, Reimbursement Risk, Cash Flow & Growth
Boston Scientific (BSX) earns a Buy rating on double-digit revenue growth, expanding EBITDA, and improving free cash flow. The key question is whether management can sustain execution while navigating reimbursement pressure and acquisition-led capital deployment.